Mereo BioPharma Group plc
MREO
$0.53
-$0.01-0.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 500.00K | 500.00K | -- | -- | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 500.00K | 500.00K | -- | -- | 1.00M |
| Cost of Revenue | 132.00K | 132.00K | -- | -- | -273.00K |
| Gross Profit | 368.00K | 368.00K | -- | -- | 1.27M |
| SG&A Expenses | 25.27M | 25.42M | 27.80M | 26.43M | 23.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.84M | 45.12M | 47.31M | 45.71M | 39.07M |
| Operating Income | -45.34M | -44.62M | -47.31M | -45.71M | -38.07M |
| Income Before Tax | -41.57M | -49.55M | -47.19M | -43.25M | -45.85M |
| Income Tax Expenses | -- | -- | -- | -- | -532.00K |
| Earnings from Continuing Operations | -41.57 | -49.55 | -47.19 | -43.25 | -45.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.57M | -49.55M | -47.19M | -43.25M | -45.32M |
| EBIT | -45.34M | -44.62M | -47.31M | -45.71M | -38.07M |
| EBITDA | -44.83M | -44.01M | -46.73M | -45.13M | -37.48M |
| EPS Basic | -1.32 | -1.58 | -1.56 | -1.46 | -1.56 |
| Normalized Basic EPS | -0.17 | -0.20 | -0.19 | -0.18 | -0.20 |
| EPS Diluted | -1.32 | -1.58 | -1.56 | -1.46 | -1.56 |
| Normalized Diluted EPS | -0.17 | -0.20 | -0.19 | -0.18 | -0.20 |
| Average Basic Shares Outstanding | 631.75M | 625.79M | 608.25M | 591.45M | 576.40M |
| Average Diluted Shares Outstanding | 126.35M | 125.16M | 121.65M | 118.29M | 115.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |